1. F. Yu. Belozertsev, I. I. Kozlovskii, T. P. Semenova, and M. M. Kozlovskaya, “Effects of the neuropeptide Selank on acquisition of an adaptive spatial visual orientation skill in rats with impaired mnestic function,” Zh. Psikhofarm. Biol. Narkol., 9, 2591–2597 (2009).
2. T. A. Gudasheva, R. U. Ostrovskaya, F. V. Maksimova, et al., “Possible structural-functional relationships between piracetam and vasopressin,” Khim.-Farm. Zh., 3, 271–275 (1988).
3. T. A. Gudasheva, R. U. Ostrovskaya, S. S. Trofimov, et al., “Peptide analogs of piracetam as ligands of presumptive nootropic receptors,” Khim.-Farm. Zh., 11, 1322–1328 (1985).
4. A. A. Zozulya, G. G. Neznamov, T. S. Syunyakov, et al., “Efficacy and mechanisms of action of the new peptide anxiolytic Selank in the treatment of generalized anxiety disorder and neurasthenia,” Zh. Nevrol. Psikhiat. im. Korsakova, 13, 201–210 (2008).
5. A. N. Chepkova, N. A. Kiapai, N. V. Doreuli, et al., “Effects of the amide pyroglutamylasparagine on the plastic properties of synaptic transmission in the hippocampus,” Byull. Eksperim. Biol. Med., 7, 68–71 (2003).